{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:44:41Z","timestamp":1787010281838,"version":"build-2736575974"},"reference-count":75,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Venetoclax has transformed the therapeutic landscape of acute myeloid leukemia (AML). Hypomethylating agents with venetoclax (HMA-VEN) have significantly improved outcomes and have become the standard therapy for older\/unfit patients with newly diagnosed AML and are comparable to intensive chemotherapy in salvage setting. Venetoclax with intensive chemotherapy have shown high response rates in both frontline and salvage setting in younger patients, and triplet combinations with HMA-VEN and FLT3 inhibitors have shown encouraging results in\n                    <jats:italic toggle=\"yes\">FLT3<\/jats:italic>\n                    <jats:sup>mut<\/jats:sup>\n                    AML. While patients with\n                    <jats:italic toggle=\"yes\">NPM1<\/jats:italic>\n                    <jats:sup>mut<\/jats:sup>\n                    ,\n                    <jats:italic toggle=\"yes\">IDH1\/2<\/jats:italic>\n                    <jats:sup>mut<\/jats:sup>\n                    experience favorable outcomes, those with\n                    <jats:italic toggle=\"yes\">TP53<\/jats:italic>\n                    <jats:sup>mut<\/jats:sup>\n                    and secondary AML may experience minimal benefit from the addition of venetoclax. Despite improved outcomes, severe cytopenias and infectious complications are common with venetoclax-based regimens. Early response evaluation, dose reductions, venetoclax interruptions, use of growth factors, and prophylactic antimicrobials may minimize such myelosuppression and risk of infections. Outcomes after failure of frontline HMA-VEN are dismal, and novel approaches are needed to abrogate primary and acquired resistance.\n                  <\/jats:p>","DOI":"10.1097\/ppo.0000000000000567","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T14:06:33Z","timestamp":1642773993000},"page":"2-13","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":25,"title":["How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia"],"prefix":"10.1097","volume":"28","author":[{"given":"Abhishek","family":"Maiti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Y.","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/bloodadvances.2017015222","article-title":"Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission","volume":"2","year":"2018","journal-title":"Blood Adv"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"116","year":"2010","journal-title":"Blood"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.clml.2016.08.006","article-title":"An evaluation of treatment patterns and outcomes in elderly patients newly diagnosed with acute myeloid leukemia: a retrospective analysis of electronic medical records from US community oncology practices","volume":"16","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1182\/bloodadvances.2018019125","article-title":"Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States","volume":"2","year":"2018","journal-title":"Blood Adv"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017","volume":"127","year":"2021","journal-title":"Cancer"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","year":"2007","journal-title":"Cancer"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","year":"2015","journal-title":"Blood"},{"key":"bib10-20250621","article-title":"Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial [Internet]","year":"2018","journal-title":"Lancet Haematol"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","year":"2009","journal-title":"N Engl J Med"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","year":"2009","journal-title":"N Engl J Med"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.leu.2403336","article-title":"Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study","volume":"18","year":"2004","journal-title":"Leukemia"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1200\/JCO.2011.37.1286","article-title":"Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study","volume":"30","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"e871","DOI":"10.1016\/j.clml.2020.06.007","article-title":"Salvage therapy outcomes in a historical cohort of patients with relapsed or refractory acute myeloid leukemia","volume":"20","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.2013.52.8562","article-title":"International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed\/refractory acute myeloid leukemia","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","year":"2013","journal-title":"Nat Med"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","year":"2014","journal-title":"Cancer Discov"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","year":"2016","journal-title":"Cancer Discov [Internet]"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","year":"2020","journal-title":"N Engl J Med"},{"issue":"suppl 15","key":"bib22-20250621","first-page":"7018","article-title":"Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine","volume":"39","year":"2021","journal-title":"J Clin Oncol"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","year":"2019","journal-title":"Blood"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-Day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","year":"2020","journal-title":"Lancet Haematol"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.26061","article-title":"Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment-related mortality","volume":"96","year":"2021","journal-title":"Am J Hematol"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1002\/cncr.33814","article-title":"Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: a propensity score\u2013matched analysis","volume":"127","year":"2021","journal-title":"Cancer"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","year":"2020","journal-title":"Blood"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","article-title":"Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy","volume":"38","year":"2020","journal-title":"J Clin Oncol"},{"key":"bib32-20250621","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-Ida induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","year":"2021","journal-title":"J Clin Oncol"},{"key":"bib33-20250621","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial","volume":"8","year":"2021","journal-title":"Lancet Haematol"},{"issue":"suppl 15","key":"bib36-20250621","first-page":"7012","article-title":"A phase Ib\/II study of ivosidenib with venetoclax +\/\u2212 azacitidine in IDH1-mutated myeloid malignancies","volume":"39","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"bib37-20250621","first-page":"370","article-title":"Quizartinib (Quiz) with decitabine (DAC) and venetoclax (VEN) is highly active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML)\u2013RAS\/MAPK mutations continue to drive primary and secondary resistance","volume":"138","year":"2021","journal-title":"Blood"},{"key":"bib38-20250621","article-title":"Preliminary results of a phase I\/II study of azacitidine, venetoclax and pevonedistat in patients with secondary acute myeloid leukemia who are unfit for intensive chemotherapy [Internet]","journal-title":"HemaSphere"},{"key":"bib39-20250621","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.3324\/haematol.2019.242826","article-title":"Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis","volume":"105","year":"2020","journal-title":"Haematologica"},{"key":"bib40-20250621","first-page":"e11","article-title":"FLA-Ida salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIda) in patients with relapsed\/refractory acute leukaemia","volume":"188","year":"2020","journal-title":"Br J Haematol"},{"key":"bib41-20250621","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/bloodadvances.2020003717","article-title":"Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia","volume":"5","year":"2021","journal-title":"Blood Adv"},{"key":"bib42-20250621","first-page":"24","article-title":"Allogeneic transplant improves AML outcomes compared to maintenance venetoclax and azacitidine following response to initial venetoclax and azacitidine therapy","volume":"136","year":"2020","journal-title":"Blood"},{"key":"bib43-20250621","first-page":"11","article-title":"Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse","volume":"136","year":"2020","journal-title":"Blood"},{"key":"bib44-20250621","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/bloodadvances.2019001267","article-title":"Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens","volume":"4","year":"2020","journal-title":"Blood Adv"},{"key":"bib45-20250621","article-title":"Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia [Internet]","year":"2020","journal-title":"Am J Hematol"},{"key":"bib46-20250621","first-page":"8","article-title":"Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with acute myeloid leukemia with FLT3 mutations","volume":"136","year":"2020","journal-title":"Blood"},{"key":"bib47-20250621","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","article-title":"Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia","volume":"25","year":"2019","journal-title":"Clin Cancer Res"},{"key":"bib48-20250621","doi-asserted-by":"crossref","first-page":"S285","DOI":"10.1016\/S2152-2650(21)01684-0","article-title":"AML-162: efficacy and safety of venetoclax in combination with gilteritinib for relapsed\/refractory FLT3-mutated acute myeloid leukemia: updated analyses of a phase 1b study","volume":"21","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"bib49-20250621","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41408-021-00410-w","article-title":"Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia","volume":"11","year":"2021","journal-title":"Blood Cancer J"},{"issue":"suppl 15","key":"bib50-20250621","first-page":"e19019","article-title":"Quizartinib with decitabine and venetoclax (triplet) is highly active in patients with FLT3-ITD mutated acute myeloid leukemia (AML)","volume":"39","year":"2021","journal-title":"J Clin Oncol"},{"key":"bib51-20250621","first-page":"E154","article-title":"Decitabine and venetoclax for IDH1\/2-mutated acute myeloid leukemia","volume":"96","year":"2021","journal-title":"Am J Hematol"},{"key":"bib52-20250621","first-page":"35","article-title":"Response patterns and MRD by flow cytometry and NGS in patients with mutant-IDH acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents","volume":"136","year":"2020","journal-title":"Blood"},{"key":"bib53-20250621","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1016\/S2152-2650(21)01697-9","article-title":"AML-212: treatment free remission (TFR) after ceasing venetoclax-based therapy in responding patients with acute myeloid leukemia","volume":"21","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"bib54-20250621","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","year":"2019","journal-title":"Cancer Discov"},{"key":"bib55-20250621","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","year":"2020","journal-title":"Blood"},{"key":"bib56-20250621","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.33689","article-title":"Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax","volume":"127","year":"2021","journal-title":"Cancer [Internet]"},{"key":"bib57-20250621","first-page":"e45","article-title":"Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia","volume":"187","year":"2019","journal-title":"Br J Haematol"},{"key":"bib58-20250621","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/bloodadvances.2017008227","article-title":"Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis","volume":"1","year":"2017","journal-title":"Blood Adv"},{"issue":"suppl 15","key":"bib59-20250621","first-page":"7011","article-title":"Venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with therapy-related myeloid neoplasms, antecedent myelodysplastic syndromes, or myelodysplastic\/myeloproliferative neoplasms","volume":"39","year":"2021","journal-title":"J Clin Oncol"},{"key":"bib60-20250621","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/bloodadvances.2020003934","article-title":"Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs","volume":"5","year":"2021","journal-title":"Blood Adv"},{"key":"bib61-20250621","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","article-title":"How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia","volume":"33","year":"2019","journal-title":"Leukemia"},{"key":"bib62-20250621","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2019001239","article-title":"How I treat acute myeloid leukemia in the era of new drugs","volume":"135","year":"2020","journal-title":"Blood"},{"key":"bib63-20250621","first-page":"E65","article-title":"Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax","volume":"96","year":"2021","journal-title":"Am J Hematol"},{"key":"bib65-20250621","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1007\/s00520-021-06119-7","article-title":"Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemia","volume":"29","year":"2021","journal-title":"Support Care Cancer"},{"key":"bib66-20250621","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1016\/S2352-3026(18)30132-7","article-title":"Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial","volume":"5","year":"2018","journal-title":"Lancet Haematol"},{"key":"bib67-20250621","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.clinthera.2014.04.013","article-title":"Cefpodoxime for antimicrobial prophylaxis in neutropenia: a retrospective case series","volume":"36","year":"2014","journal-title":"Clin Ther"},{"key":"bib68-20250621","first-page":"CD000026","article-title":"Routine versus selective antifungal administration for control of fungal infections in patients with cancer","year":"2002","journal-title":"Cochrane Database Syst Rev [Internet]"},{"key":"bib69-20250621","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/cid\/ciaa358","article-title":"Isavuconazole as primary antifungal prophylaxis in patients with acute myeloid leukemia or myelodysplastic syndrome: an open-label, prospective, phase 2 study","volume":"72","year":"2021","journal-title":"Clin Infect Dis"},{"key":"bib70-20250621","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/cid\/ciaa652","article-title":"Isavuconazole is as effective as and better tolerated than voriconazole for antifungal prophylaxis in lung transplant recipients","volume":"73","year":"2021","journal-title":"Clin Infect Dis"},{"key":"bib71-20250621","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.bbmt.2020.02.009","article-title":"A single-center, open-label trial of Isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic cell transplantation","volume":"26","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"bib72-20250621","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib73-20250621","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00277-015-2447-3","article-title":"Antiviral prophylaxis in patients with solid tumours and haematological malignancies\u2014update of the guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)","volume":"94","year":"2015","journal-title":"Ann Hematol"},{"key":"bib74-20250621","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S2152-2650(21)01190-3","article-title":"Beyond BCL-2 inhibition in acute myeloid leukemia: other approaches to leverage the apoptotic pathway","volume":"21","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"bib75-20250621","first-page":"894","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens","volume":"106","year":"2021","journal-title":"Haematologica"},{"key":"bib76-20250621","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","year":"2020","journal-title":"Cancer Discov"},{"key":"bib77-20250621","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood.2020009081","article-title":"Venetoclax enhances T cell\u2013mediated antileukemic activity by increasing ROS production","volume":"138","year":"2021","journal-title":"Blood"},{"key":"bib78-20250621","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","article-title":"Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade","volume":"11","year":"2021","journal-title":"Cancer Discov"},{"key":"bib79-20250621","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1038\/s41409-021-01245-6","article-title":"Venetoclax does not impair activated T-cell proliferation","volume":"56","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"bib80-20250621","doi-asserted-by":"crossref","first-page":"608167","DOI":"10.3389\/fimmu.2020.608167","article-title":"Pre-sensitization of malignant B cells through venetoclax significantly improves the cytotoxic efficacy of CD19.CAR-T cells","volume":"11","year":"2020","journal-title":"Front Immunol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000567","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T13:00:42Z","timestamp":1750510842000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000567","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}